z-logo
open-access-imgOpen Access
Severe Relapsing Goodpasture's Disease Successfully Treated with Mycophenolate Mofetil
Author(s) -
Anabela Malho Guedes,
Viriato Santos,
Ana Cabrita,
Ana Paula Silva,
Isabel Pinto,
Idalécio Bernardo,
Pedro Leão Neves
Publication year - 2010
Publication title -
international journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.551
H-Index - 29
eISSN - 2090-2158
pISSN - 2090-214X
DOI - 10.4061/2010/383548
Subject(s) - medicine , mycophenolate , goodpasture's syndrome , prednisolone , rapidly progressive glomerulonephritis , immunosuppression , refractory (planetary science) , disease , immunology , gastroenterology , dermatology , glomerulonephritis , transplantation , vasculitis , kidney , physics , astrobiology
Goodpasture's disease is a rare autoimmune disorder characterised by the development of antiglomerular basement membrane autoantibodies, which typically presents with rapidly progressive crescentic glomerulonephritis and pulmonary haemorrhage. Even with aggressive nonspecific immunosuppression and plasma exchange, mortality remains high. We report a case of life-threatening Goodpasture's disease with relapsing pulmonary haemorrhage refractory to conventional therapy. Second line treatment was based on mycophenolate mofetil 1 g every 12 hours and prednisolone 60 mg/day. In this case, the use of a low-dose mycophenolate mofetil regimen turned out to be insufficient. However, in our opinion higher mycophenolate mofetil doses should be considered an alternative treatment, mainly in relapsing disease, due to its mechanism of action and current insufficient therapeutic weapons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom